Protherics Initiates Phase IIb Study in Oesophageal Cancer
Posted on: Monday, 28 January 2008, 09:01 CST
Biopharmaceutical firm Protherics has enrolled the first patient in a multinational, randomized, Phase IIb study of OncoGel, a novel locally-administered sustained-release formulation of paclitaxel for the treatment of solid tumours.
The study will evaluate OncoGel administered in combination with pre-operative chemoradiotherapy versus pre-operative chemoradiotherapy alone in 124 patients. The primary endpoint of the study is a blinded assessment of tumor response, overall survival is one of the secondary endpoints. Protherics expects to have preliminary data available from the Phase IIb study in the first half of 2010.
Andrew Heath, CEO of Protherics, said: "Following the encouraging Phase IIa study, we are hopeful that the Phase IIb study will provide further data to support the use of OncoGel as a potential treatment to increase the life expectancy for people with oesophageal cancer, a particularly devastating cancer."
Source: Datamonitor
Related Articles
- DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
- Protherics Reports Positive Data From Phase IIb Pre-Eclampsia Study
- Protherics Completes Enrollment for Phase IIb Pre-Eclampsia Study
- Increased Bone Mineral Density Seen in Phase IIB Study With Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
- Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
- Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis With CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101
- Can-Fite Submitted Its Protocol for a Phase IIb Clinical Study of CF101
- Preliminary Phase IIb Study Data Demonstrate Rylomine(TM) Significantly Reduces Postsurgical Orthopedic Pain
- Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Experienced HIV Patients Failing Current Treatment Regimen; Findings Presented at the 3rd International AIDS Society Conference
 |
 |
User Comments (0)
RSS Feeds